+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

In-Vitro Fertilization (IVF) Market Size, Share & Trends Analysis Report By Type, By Instrument (Disposable Devices, Culture Media, Capital Equipment), By End Use, By Region, And Segment Forecasts, 2019 - 2026

  • ID: 4761221
  • Report
  • 100 pages
  • Grand View Research
1 of 3

FEATURED COMPANIES

  • Bayer Ag
  • Cook Medical (Cook Group)
  • Ferring Pharmaceutical
  • Irvine Scientific
  • ORGANON
  • Ovascience, Inc.
  • MORE
The global in-vitro fertilization market size is expected to reach USD 36.2 billion by 2026, based on this report. It is projected to expand at a CAGR of 10.2% during the forecast period. The market is driven by the increasing incidence of infertility owing to lifestyle changes, government initiatives to provide better reimbursement policies, and the continuous efforts by the industry contributors. Expansion of fertility procedures for treating male infertility such as ICSI, is projected to positively influence the growth in near future.

Moreover, availability of genomic testing with the ability to prevent the transfer of genetic disease during IVF procedure is expected to drive the market. Increasing number of IVF treatments has encouraged more insurance providers to cover these procedures. This has ultimately led to competitive pricing and has moderated the treatment costs, driving the market with more treatment standardization and automation.

The behavioral shift in the society is the major factor contributing to the decreased Total Fertility Rate (TFR). This shift reflects on increasing number of working women, advanced maternal age, a shift from rural to urban societies, lower marriage rates, and delaying marriages. Such factors are projected to drive the in-vitro fertilization market during the forecast period.

Obesity is another factor leading to an increase in infertility. The fat deposited on women’s abdomen prevents follicular stimulation and produces male hormones. In case of males, rising fat deposits decrease testosterone levels and can result in lowered sperm production. Doctors recommend weight loss in men prior to fertility treatments along with proper maintenance of Body Mass Index (BMI). The U.S. Endocrine Society has established the use of Letrozole to increase the testosterone levels in obese patients.

The presence of favorable reimbursement framework, such as implementation of USD 50 million 5-year plans by the U.S Department of Defense for sperm/egg freezing coverage, is expected to drive the regional growth over the next six years. Increasing number of clinics undertaking newer techniques to offer better fertility success rates is also expected to boost the regional demand.

In Europe, the NHS covers three IVF cycles and provides coverage for gametes freezing. Moreover, the region is an attraction for international clients as countries, as countries such as Spain, have the highest number of egg donors. The clinics also provide sex identification and other IVF treatments, which are not offered in North America.

The Asia Pacific Initiative on Reproduction (ASPIRE) consists of a task force of clinicians and scientists involved in monitoring and managing fertility and Assisted Reproductive Technology (ART). Such initiatives promote awareness levels among consumers thereby, driving the growth of the IVF market.

Industry contributors are introducing advanced automation to shift the IVF treatment from invasive to minimally invasive or non-invasive procedure. The industry players are also working on technologies, which can enable older women to have enhanced fertility rates. In August 2015, OvaScience announced the results of its first published analysis comparing AUGMENT fertility treatment with a standard IVF. The results showed a significantly higher rate of selection and transfer of embryos as compared to the standard treatment.

Further key findings from the study suggest:
  • Culture media led the overall market in terms of revenue in 2018. With the increasing government funding and industrial support for employees for egg/sperm freezing, the demand for cryopreservation and the required media for it, is expected to witness growth
  • Increasing number of egg/sperm donor banks is expected to drive the demand for sperm, egg, and embryo processing media during the forecast period
  • Fresh non-donor segment led the market in 2018. According to the 2003 - 2012 trends by the CDC, the number of fresh non-donors banking the eggs/embryos has drastically increased in U.S
  • Europe led the in-vitro fertilization procedure and instrument market in 2018. High quality of treatment at economical prices and the adherence to medical standards have contributed to its market leadership
  • North America also accounted for a significant market share in 2018. The standardization of procedures through automation, regulatory reforms, government funding for egg/sperm storage, and industry players introducing more IVF treatments are some contributing factors for the regional growth
  • The demand for IVF treatment is expected to boom in APAC owing to fertility tourism and increasing penetration and awareness regarding the treatment in the developing economies
  • Some key players in the In-vitro Fertilization (IVF) market include EMD Serono Inc.; Boston IVF; OvaScience; Thermo Fisher Scientific Inc.; Vitrolife AB; Irvine Scientific; CooperSurgical, Inc.; Cook Medical Inc.; Genea Biomedx; and Progyny Inc.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bayer Ag
  • Cook Medical (Cook Group)
  • Ferring Pharmaceutical
  • Irvine Scientific
  • ORGANON
  • Ovascience, Inc.
  • MORE
Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased Database:
1.3.2 Internal database
1.3.3 Secondary Sources:
1.3.4 Primary Research
1.4 Information or Data Analysis
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective - 1:
1.10.2 Objective - 2:

Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights

Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Market Segmentation
3.3 Penetration & Growth Prospect Mapping
3.4 Clinical Trials
3.5 User Perspective Analysis
3.5.1 Consumer Behavior Analysis
3.5.2 Market Influencer Analysis
3.6 Regulatory Framework & Reimbursement Scenario
3.6.1 North America
3.6.2 Europe
3.6.3 Asia Pacific
3.6.4 Latin America
3.6.5 Middle East & Africa
3.7 Market Dynamics
3.7.1 Market Driver Analysis
3.7.1.1 Rising reprotourism
3.7.1.2 Technological advancements in IVF
3.7.1.3 Favorable government funding
3.7.1.4 Late initiation of family
3.7.1.5 Increasing incidence rate of male and female infertility
3.7.1.6 Mergers and acquisitions (M&A)
3.7.2 Market Restraint Analysis
3.7.2.1 High cost of IVF treatment
3.7.2.2 Lack of regulatory framework and uniform regulations
3.7.3 Porter’s Five Forces Analysis
3.7.3.1 Bargaining power of buyers: Low
3.7.3.2 Bargaining power of suppliers: Moderate
3.7.3.3 Competitive rivalry: High
3.7.3.4 Threat of new entrants: Moderate
3.7.3.5 Threat of substitutes: Low
3.8 Business Environment Analysis Tools
3.8.1 Swot Analysis, By Pestel
3.8.1.1 Political & legal
3.8.1.2 Economic
3.8.1.3 Technological
3.8.2 Major Deals & Strategic Alliances Analysis
3.8.2.1 Joint ventures
3.8.2.2 Mergers & acquisitions
3.9 Number of IVF Cycles, by Region, 2018

Chapter 4 In-Vitro Fertilization (IVF) Market: Instrument Analysis
4.1 In-Vitro Fertilization (IVF) Market Share Analysis, 2018 & 2026
4.2 Segment Dashboard
4.3 Global In-Vitro Fertilization (IVF) Market, by Instrument, 2018 to 2026
4.4 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the Instrument
4.4.1 Culture Media
4.4.1.1 Culture media market, 2015 - 2026 (USD Million)
4.4.2 Disposable Devices
4.4.2.1 Disposable devices market, 2015 - 2026 (USD Million)
4.4.3 Capital Equipment
4.4.3.1 Capital equipment market, 2015 - 2026 (USD Million)

Chapter 5 In-Vitro Fertilization (IVF) Market: Type Analysis
5.1 IVF by Type Market Share Analysis, 2018 & 2026
5.2 Segment Dashboard
5.3 Global IVF Market, by Treatment Type, 2015 to 2026
5.4 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the Treatment Type
5.4.1 Fresh Nondonor
5.4.1.1 Fresh nondonor market, 2015 - 2026 (USD Million)
5.4.2 Frozen Nondonor
5.4.2.1 Frozen nondonor market, 2015 - 2026 (USD Million)
5.4.3 Fresh Donor
5.4.3.1 Fresh donor market, 2015 - 2026 (USD Million)
5.4.4 Frozen Donor
5.4.4.1 Frozen donor market, 2015 - 2026 (USD Million)

Chapter 6 In-Vitro Fertilization (IVF) Market: End-Use Analysis
6.1 In-Vitro Fertilization (IVF) End Use Market Share Analysis, 2018 & 2026
6.2 Segment Dashboard
6.3 Global In-Vitro Fertilization (IVF) Market, by End Use, 2018 to 2026
6.4 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the Following End Use
6.4.1 Fertility Clinics
6.4.1.1 Fertility clinics market, 2015 - 2026 (USD Million)
6.4.2 Hospitals And Others
6.4.2.1 Hospitals and others market, 2015 - 2026 (USD Million)

Chapter 7 Regional Outlook
7.1 Definitions & Scope
7.2 Regional Market Share Analysis, 2018 & 2026
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.6 Market Size, & Forecasts and Trend Analysis, 2018 to 2026
7.6.1 North America
7.6.1.1 North America in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.1.2 U.S.
7.6.1.2.1 U.S. in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.1.3 Canada
7.6.1.3.1 Canada in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.2 Europe
7.6.2.1 Europe in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.2.2 UK
7.6.2.2.1 UK in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.2.3 Germany
7.6.2.3.1 Germany in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.2.4 France
7.6.2.4.1 France in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.2.5 Italy
7.6.2.5.1 Italy in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.2.6 Spain
7.6.2.6.1 Spain in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.2.7 Netherlands
7.6.2.7.1 Netherlands in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.2.8 Switzerland
7.6.2.8.1 Switzerland in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.2.9 Belgium
7.6.2.9.1 Belgium in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.3 ASIA PACIFIC
7.6.3.1 Asia Pacific in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.3.2 Japan
7.6.3.2.1 Japan in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.3.3 China
7.6.3.3.1 China (Mainland) in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.3.4 India
7.6.3.4.1 India in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.4 Latin America
7.6.4.1 Latin America in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.4.2 Brazil
7.6.4.2.1 Brazil in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.4.3 Mexico
7.6.4.3.1 Mexico in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.5 Middle East And Africa
7.6.5.1 MEA in-vitro fertilization market, 2015 - 2026 (USD Million)
7.6.5.2 South Africa
7.6.5.2.1 South Africa in-vitro fertilization market, 2015 - 2026 (USD Million)

Chapter 8 Competitive Analysis
8.1 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players
8.2 Vendor Landscape
8.2.1 Strategy Mapping
8.2.2 Launch Of New Products:
8.2.3 Merger And Acquisition:
8.2.4 Geographical Expansion:
8.2.5 Partnerships:
8.3 Public Companies
8.3.1 Company Market Position Analysis (Revenue, Geographic Presence, Product Portfolio, Key Serviceable Industries, Key Alliances)
8.4 Private Companies
8.4.1 List Of Key Emerging Companies/Technology
8.4.2 Company Market Position Analysis (Geographic Presence, Product Portfolio, Key Alliance, Industry Experience)
8.5 Company Profiles
8.5.1 OVASCIENCE, INC.
8.5.1.1 Company overview
8.5.1.2 Financial performance
8.5.1.3 Product benchmarking
8.5.1.4 Strategic initiatives
8.5.1.5 SWOT analysis
8.5.2 VITROLIFE
8.5.2.1 Company overview
8.5.2.2 Financial performance
8.5.2.3 Product benchmarking
8.5.2.4 Strategic initiatives
8.5.2.5 SWOT analysis
8.5.3 EMD SERONO, INC.
8.5.3.1 Company overview
8.5.3.2 Financial performance
8.5.3.3 Product benchmarking
8.5.3.4 Strategic initiatives
8.5.3.5 SWOT analysis
8.5.4 IRVINE SCIENTIFIC
8.5.4.1 Company overview
8.5.4.2 Financial performance
8.5.4.3 Product benchmarking
8.5.4.4 Strategic initiatives
8.5.4.5 SWOT analysis
8.5.5 THE COOPER COMPANIES, INC.
8.5.5.1 Company overview
8.5.5.2 Product benchmarking
8.5.5.3 SWOT analysis
8.5.6 COOK MEDICAL (COOK GROUP)
8.5.6.1 Company overview
8.5.6.2 Product benchmarking
8.5.6.3 Strategic initiatives
8.5.6.4 SWOT analysis
8.5.7 THERMO FISHER SCIENTIFIC, INC.
8.5.7.1 Company overview
8.5.7.2 Financial performance
8.5.7.3 Product benchmarking
8.5.7.4 Strategic initiatives
8.5.7.5 SWOT analysis
8.5.8 GENEA BIOMEDX
8.5.8.1 Company overview
8.5.8.2 Product benchmarking
8.5.8.3 Strategic initiatives
8.5.8.4 SWOT analysis
8.5.9 PROGYNY, INC.
8.5.9.1 Company overview
8.5.9.2 Financial performance
8.5.9.3 Product benchmarking
8.5.9.4 Strategic initiatives
8.5.9.5 SWOT analysis
8.5.10 BOSTON IVF
8.5.10.1 Company overview
8.5.10.2 Financial performance
8.5.10.3 Product benchmarking
8.5.10.4 Strategic initiatives
8.5.10.5 SWOT analysis
8.5.11 ORIGIO
8.5.11.1 Company overview
8.5.11.2 Financial performance
8.5.11.3 Product benchmarking
8.5.11.4 Strategic initiatives
8.5.11.5 SWOT analysis
8.5.12 FERRING PHARMACEUTICAL
8.5.12.1 Company overview
8.5.12.2 Financial performance
8.5.12.3 Product benchmarking
8.5.12.4 Strategic initiatives
8.5.12.5 SWOT analysis
8.5.13 BAYER AG
8.5.13.1 Company overview
8.5.13.2 Financial performance
8.5.13.3 Product benchmarking
8.5.13.4 Strategic initiatives
8.5.13.5 SWOT analysis
8.5.14 MERCK & CO., INC.
8.5.14.1 Company overview
8.5.14.2 Financial performance
8.5.14.3 Product benchmarking
8.5.14.4 Strategic initiatives
8.5.14.5 SWOT analysis
8.5.15 ORGANON
8.5.15.1 Company overview
8.5.15.2 Financial performance
8.5.15.3 Product benchmarking
8.5.15.4 Strategic initiatives
8.5.15.5 SWOT analysis

Chapter 9 KOL Commentary & Recommendations

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Ovascience, Inc.
  • Vitrolife
  • Emd Serono, Inc.
  • Irvine Scientific
  • The Cooper Companies, Inc.
  • Cook Medical (Cook Group)
  • Thermo Fisher Scientific, Inc.
  • Genea Biomedx
  • Progyny, Inc.
  • Boston Ivf
  • Origio
  • Ferring Pharmaceutical
  • Bayer Ag
  • Merck & Co., Inc.
  • ORGANON
Note: Product cover images may vary from those shown
Adroll
adroll